Analyst Craig Hettenbach of Morgan Stanley maintained a Buy rating on Ardent Health Partners, Inc. (ARDT – Research Report), reducing the price target to $22.00. Craig Hettenbach has given his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback